GLP-1 Drug Effects on Cancer Risk: Comprehensive Efficacy and Safety Analysis
Analysis of GLP-1 receptor agonist effects on cancer outcomes examines whether these metabolic drugs influence cancer risk, progression, or mortality.
Quick Facts
What This Study Found
Analysis of GLP-1 receptor agonist effects on cancer outcomes examines whether these metabolic drugs influence cancer risk, progression, or mortality.
Key Numbers
Network meta-analysis through December 2024 from four databases comparing individual GLP-1 drugs for comprehensive cardiovascular outcomes.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Analysis of GLP-1 receptor agonist effects on cancer outcomes examines whether these metabolic drugs
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.
- Published In:
- Diabetes, obesity & metabolism, 27(4), 1735-1751 (2025)
- Authors:
- An, Xuedong, Sun, WenJie, Wen, Zhige, Duan, LiYun, Zhang, YueHong, Kang, Xiaomin, Ji, Hangyu, Sun, Yuting, Jiang, Linlin, Zhao, Xuefei, Gao, Qing, Lian, Fengmei
- Database ID:
- RPEP-09935
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Analysis of GLP-1 receptor agonist effects on cancer outcomes examines whether these metabolic drugs influence cancer risk, progression, or mortality.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09935APA
An, Xuedong; Sun, WenJie; Wen, Zhige; Duan, LiYun; Zhang, YueHong; Kang, Xiaomin; Ji, Hangyu; Sun, Yuting; Jiang, Linlin; Zhao, Xuefei; Gao, Qing; Lian, Fengmei. (2025). Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.. Diabetes, obesity & metabolism, 27(4), 1735-1751. https://doi.org/10.1111/dom.16228
MLA
An, Xuedong, et al. "Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.." Diabetes, 2025. https://doi.org/10.1111/dom.16228
RethinkPeptides
RethinkPeptides Research Database. "Comparison of the efficacy and safety of GLP-1 receptor agon..." RPEP-09935. Retrieved from https://rethinkpeptides.com/research/an-2025-comparison-of-the-efficacy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.